Table 1 Patient characteristics and 5-year survival in derivation cohort and validation cohort
Characteristics | Derivation cohort | Validation cohort | P-values between cohorts | ||||||
|---|---|---|---|---|---|---|---|---|---|
Derivation cohort (n = 64) | 5-year survival (n = 31) | 5-year death (n = 33) | P-values | Validation cohort (n = 31) | 5-year survival (n = 14) | 5-year death (n = 17) | P-values | ||
5-Year mortality | 33 (51.6%) | Â | Â | Â | 17 (54.8%) | Â | Â | Â | 0.8285 |
Male sex (%) | 50 (78.1%) | 21 (66.7%) | 29 (87.9%) | 0.0713 | 21 (67.7%) | 8 (57.1%) | 13 (76.5%) | 0.4414 | 0.3181 |
Age(yr) | 69.7 ± 6.7 | 69.1 ± 6.5 | 70.3 ± 6.8 | 0.4847 | 71.4 ± 8.4 | 70.4 ± 8.5 | 72.3 ± 8.5 | 0.5340 | 0.2843 |
FVC(L) | 2.3 ± 0.6 | 2.3 ± 0.7 | 2.3 ± 0.6 | 0.8179 | 2.3 ± 0.8 | 2.1 ± 0.4 | 2.4 ± 1.0 | 0.4290 | 0.7059 |
FVC%pred(%) | 68.1 ± 16.8 | 70.7 ± 16.4 | 65.1 ± 17.2 | 0.2695 | 67.3 ± 17.2 | 63.3 ± 13.8 | 70.5 ± 19.7 | 0.4297 | 0.8708 |
DLCO(mmol/min/kPa) | 5.0 ± 4.2 | 5.6 ± 4.3 | 4.3 ± 4.1 | 0.3286 | 5.8 ± 4.2 | 6.3 ± 4.6 | 4.6 ± 5.5 | 0.7767 | 0.5488 |
DLCO%pred(%) | 49.1 ± 21 | 57.6 ± 22.4 | 39.3 ± 14.4 | 0.0033 | 45.7 ± 17.8 | 48.5 ± 23.5 | 43.2 ± 12.7 | 0.6189 | 0.5935 |
KCO(mmol/min/kPa/L) | 1.3 ± 1.1 | 1.5 ± 1.2 | 1.2 ± 0.9 | 0.3262 | 1.5 ± 1.2 | 1.6 ± 1.7 | 1.4 ± 0.8 | 0.7911 | 0.6226 |
KCO%pred(%) | 66.4 ± 21.7 | 75 ± 21.9 | 57.6 ± 22.4 | 0.0067 | 57.4 ± 27.3 | 52.9 ± 37.7 | 61.9 ± 12.1 | 0.5595 | 0.2236 |
GAP index | 4.3 ± 1.8 | 3.8 ± 2 | 4.9 ± 1.5 | 0.0420 | 4.4 ± 1.8 | 5.0 ± 1.9 | 3.9 ± 1.6 | 0.2459 | 0.8347 |
Baseline CTFLV//TLV%(%) | 20.4 ± 13.5 | 10.7 ± 7.1 | 29.6 ± 11.6 |  < 0.0001 | 24.5 ± 17.6 | 10.6 ± 7.2 | 36.0 ± 15.1 |  < 0.0001 | 0.2137 |